Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Account Payables (2023 - 2025)

CG Oncology's Change in Account Payables history spans 3 years, with the latest figure at -$3.5 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 242.52% year-over-year to -$3.5 million; the TTM value through Dec 2025 reached -$1.6 million, down 150.2%, while the annual FY2025 figure was -$1.6 million, 150.2% down from the prior year.
  • Change in Account Payables reached -$3.5 million in Q4 2025 per CGON's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.4 million in Q4 2024 to a low of -$3.5 million in Q4 2025.
  • Average Change in Account Payables over 3 years is $303583.3, with a median of $304000.0 recorded in 2025.
  • The largest YoY upside for Change in Account Payables was 15844.44% in 2024 against a maximum downside of 442.86% in 2024.
  • A 3-year view of Change in Account Payables shows it stood at $1.4 million in 2023, then skyrocketed by 76.63% to $2.4 million in 2024, then crashed by 242.52% to -$3.5 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Change in Account Payables are -$3.5 million (Q4 2025), $1.2 million (Q3 2025), and $394000.0 (Q2 2025).